Thu, Jul 24, 2014, 2:49 AM EDT - U.S. Markets open in 6 hrs 41 mins

Recent

% | $
Click the to save as a favorite.

OriginOil, Inc. Message Board

dmchine 8 posts  |  Last Activity: 12 hours ago Member since: Jan 10, 2011
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Business plan

    by maineman827 Jul 16, 2014 10:43 AM

    sounds like a winner

  • Reply to

    Business plan

    by maineman827 Jul 16, 2014 10:43 AM

    works for me...

  • Reply to

    targeting sleep disorder products

    by insidrtrader Jul 17, 2014 12:01 PM

    sounds like a plan!

  • Investors looking to generate substantial gains over the coming years may want to take a look at the our small-cap biotechnology companies mentioned in this article. Although each company has its own set of risks, the potential that each company offers cannot be disputed. The four companies are Ariad Pharmaceuticals (NASDAQ:ARIA), Bristol-Myers Squibb Company (NYSE:BMY), and Sanomedics International Holdings (SIMH.PK).

    One of the most actively traded biotechnology stocks over the past few months has been Ariad Pharmaceuticals. Ariad Pharmaceuticals is an integrated global oncology company focused on transforming the lives of cancer patients with breakthrough medicines. The company is working on developing new drugs for the treatment of chronic and acute leukemia, lung cancer, and other difficult-to-treat cancers.

    Although Ariad Pharmaceuticals had a rough 2013 because of a series of FDA setbacks, the company is back on track. Over the past 3 months, shares of Ariad Pharmaceuticals have climbed by roughly 255 percent thanks to several positive developments and takeout chatter.

    One of the biggest sparks for Ariad shares occurred in late November 2013 when the Committee for Human Medicinal Products of the European Medicines Agency gave a positive opinion on the continued availability of Iclusig in the European Union for use in patients in its authorized indications. Those indications included:
    The treatment of adult patients with chronic phase, accelerated phase or blast phase chronic myeloid leukemia (or, CML).
    The treatment of adult patients with Philadelphia-chromosome positive acute lymphoblastic leukemia.

  • Nice hump day - up 10%

  • OriginOil’s Electro Water Separation Technology Selected by E3 for Water Reclamation Projects

    OriginOil Inc. June 24, 2014 3:01 AM

    LOS ANGELES & MEMPHIS, Tenn.--(BUSINESS WIRE)--

    OriginOil Inc. (OTC/QB: OOIL), developer of Electro Water Separation™ (EWS), the high-speed, chemical-free process to clean up large quantities of water, announced today that E3 Services and Solutions, LLC (E3), an acquirer and integrator of industrial technologies in fuel, food and health sectors, has agreed to license EWS for integration in systems designed to reclaim water from hydraulic fracturing and industrial operations.

    Memphis, Tennessee based E3 intends to develop and further commercialize key OriginOil technologies for oil and gas water reclamation, aquaculture and feed stock production. E3 also plans to partner with OriginOil on research and development projects to further refine the company’s suite of technologies in the field.

    “E3 is unique in that we are bringing together a number of technologies focused on the water matrix. Essential to this strategy is finding best-in-breed technologies, acquiring them and deploying services around those same technologies on a global basis,” said Mark A. Skoda, CEO of E3. “Our initial markets include oil and gas drilling, mining, agriculture and aquaculture. We believe our business development process combined with our strong domain expertise allows E3 to rapidly launch these services together with our partners, such as OriginOil, quickly with world class technology. With our deep relationships in the oil services sector and our current business development efforts with a Fortune 50 oil producer, we believe we are well positioned to rapidly get these technologies into the market.”

  • Posted at SeekingAlpha

    Summary
    Medical device industry set to grow 4.4% annually, outpacing drug industry.
    Good chance for a repeal of the medical device excise tax in 2014.
    MDT, SI, GE and SIMH offer investors a good way to play the industry.

    Patent-winning drugs often steal the headlines but medical devices include some of the greatest inventions of our time.

    Pacemakers, replacement heart valves, artificial joints and brain scanners are all examples of medical devices that have changed our world and helped shape the pharmaceutical industry into what it is today.

    In this article I look at the medical device industry as a whole and give my 4 top medical device stocks for the year.

  • From the website:

    Sanomedics International Holdings, Inc. (SIMH) is a medical technology holding company that focuses on game changing products, services and ideas - a place where physicians, entrepreneurs, and medical companies can work together to drive innovative technologies through concept, development, and ultimately commercialization. We plan to grow our existing business organically and through strategic acquisitions specifically relating to sleep disorder diagnosis treatments. Sanomedics seeks to acquire sleep therapy operating businesses and our strategy is to integrate a portfolio of world-class products and service providers in the growing Sleep Apnea market. Our goal is to provide Sleep Apnea patients with a reliable and integrated "end-to-end" service platform

OOIL
0.18+0.01(+6.51%)Jul 23 3:57 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Facebook, Inc.
NasdaqGSWed, Jul 23, 2014 4:00 PM EDT
Xilinx Inc.
NasdaqGSWed, Jul 23, 2014 4:00 PM EDT